Moreover, a previous study showed the induction of aromatase expression in cervical carcinomas and opened the possibility that the use of aromatase inhibitors (AIs) for primary breast cancer may be a potential favorable factor in the development of subsequent cervical cancer [11]. This evidence concerns the gene CYP19A1 and cervical cancer.